Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report

被引:1
|
作者
Chang, Haiyan [1 ]
Hu, Ting [1 ]
Hu, Jie [1 ]
Ding, Teng [2 ]
Wang, Qiong [1 ,3 ]
Cheng, Jing [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[2] Zai Lab Shanghai Co Ltd, Med Affairs Dept, Shanghai, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Oncol, Union Hosp, Tongji Med Coll, 109 Machang Rd, Wuhan, Hubei, Peoples R China
关键词
breast cancer; human epidermal growth factor receptor 2; liver metastasis; margetuximab; TRASTUZUMAB; POLYMORPHISMS; BENEFIT;
D O I
10.1097/CAD.0000000000001466
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer has a poor prognosis and few effective targeted therapies. However, several anti-HER2 agents are emerging in conjunction with chemotherapy, which may lead to increased rates of pathological complete response in patients with HER2-positive metastatic breast cancer. Among them, margetuximab demonstrated a significant improvement in progression-free survival compared with trastuzumab, when combined with chemotherapy in pretreated patients. Here we present a case of a 67-year-old female patient who was diagnosed with HER2-positive, histological grade III and invasive ductal carcinoma of the left breast in September 2018. She received postoperative adjuvant therapy with EC-TH plus radiotherapy, followed by therapy with HER2-targeted trastuzumab for 1 year (till December 2019). In May 2020, routine reexamination showed a supraclavicular lymph node and bone metastasis. Patient was then treated with pyrotinib, capecitabine and bisphosphonate for a period of 3 months. In December 2020, liver MRI revealed multiple liver metastases. The patient received eight cycles of second-line therapy (vinorelbine plus margetuximab) from January 2021. Since the ninth cycle, the patient was continued with only margetuximab. In March 2021, MRI showed a 70% decrease in the liver metastasis lesions. By June 2021, liver lesions were totally disappeared. During therapy, patient experienced only grade-1 anemia. This case demonstrates that margetuximab plus chemotherapy is safe and might bring clinical benefits for patients with HER2-positive breast cancer with liver metastasis. Further studies evaluating the efficacy and safety of margetuximab in Chinese HER2-positive breast cancer patients are needed.
引用
收藏
页码:883 / 887
页数:5
相关论文
共 50 条
  • [21] Adjuvant Therapy for HER2-Positive Breast Cancer
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (12): : 1134 - 1134
  • [22] Targeted Therapy in HER2-Positive Breast Cancer
    Thill, Marc
    Kraft, Clayton
    Friedrich, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) : 295 - 302
  • [23] Therapy for HER2-Positive Metastatic Breast Cancer
    Dekker, Tim J. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
  • [24] Therapy Standards in HER2-Positive Breast Cancer
    Gluz, Oleg
    Liedtke, Cornelia
    Marme, Frederik
    Thill, Marc
    BREAST CARE, 2016, 11 (02) : 148 - 150
  • [25] Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis
    Niikura, Naoki
    Shimomura, Akihiko
    Fukatsu, Yumi
    Sawaki, Masataka
    Ogiya, Rin
    Yasojima, Hiroyuki
    Fujisawa, Tomomi
    Yamamoto, Mitsugu
    Tsuneizumi, Michiko
    Kitani, Akira
    Watanabe, Junichiro
    Matsui, Akira
    Takahashi, Yuko
    Takashima, Seiki
    Shien, Tadatoshi
    Tamura, Kenji
    Saji, Shigehira
    Masuda, Norikazu
    Tokuda, Yutaka
    Iwata, Hhiroji
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (01) : 81 - 87
  • [26] Neoadjuvant trastuzumab in HER2-positive breast cancer, is pathological complete response enough?
    Ruvalcaba-Limon, Eva
    Pozo-Romero, Mariela
    Bautista-Pina, Veronica
    Tenorio-Torres, Alberto
    Morales-Vazquez, Flavia
    Rodriguez-Cuevas, Sergio
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 342 - 344
  • [27] Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis
    Naoki Niikura
    Akihiko Shimomura
    Yumi Fukatsu
    Masataka Sawaki
    Rin Ogiya
    Hiroyuki Yasojima
    Tomomi Fujisawa
    Mitsugu Yamamoto
    Michiko Tsuneizumi
    Akira Kitani
    Junichiro Watanabe
    Akira Matsui
    Yuko Takahashi
    Seiki Takashima
    Tadatoshi Shien
    Kenji Tamura
    Shigehira Saji
    Norikazu Masuda
    Yutaka Tokuda
    Hhiroji Iwata
    Breast Cancer Research and Treatment, 2018, 167 : 81 - 87
  • [28] Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis
    Shimomura, A.
    Niikura, N.
    Fukatsu, Y.
    Sawaki, M.
    Ogiya, R.
    Yasojima, H.
    Fujisawa, T.
    Yamamoto, M.
    Tsuneizumi, M.
    Kitani, A.
    Watanabe, J.
    Matsui, A.
    Takahashi, Y.
    Takashima, S.
    Shien, T.
    Tamura, K.
    Saji, S.
    Masuda, N.
    Tokuda, Y.
    Iwata, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Takeo Fujii
    Takahiro Kogawa
    Jimin Wu
    Aysegul A Sahin
    Dian D Liu
    Mariana Chavez-MacGregor
    Sharon H Giordano
    Akshara Raghavendra
    Rushmy K Murthy
    Debu Tripathy
    Yu Shen
    Jose-Miguel Yamal
    Naoto T Ueno
    British Journal of Cancer, 2017, 116 : 509 - 514
  • [30] Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Fujii, Takeo
    Kogawa, Takahiro
    Wu, Jimin
    Sahin, Aysegul A.
    Liu, Dian D.
    Chavez-MacGregor, Mariana
    Giordano, Sharon H.
    Raghavendra, Akshara
    Murthy, Rushmy K.
    Tripathy, Debu
    Shen, Yu
    Yamal, Jose-Miguel
    Ueno, Naoto T.
    BRITISH JOURNAL OF CANCER, 2017, 116 (04) : 509 - 514